Երկիր: Իռլանդիա
Լեզու: անգլերեն
Աղբյուրը: HPRA (Health Products Regulatory Authority)
SODIUM IBANDRONATE MONOHYDRATE
Arrow ApS
150 Milligram
Tablets
2010-11-05
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ibandronic Acid Arrow 150 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 150 mg of Ibandronic Acid (as sodium ibandronate monohydrate). Excipient: Contains 50.70 mg Sorbitol For a full list of excipients, see Section 6.1 3 PHARMACEUTICAL FORM Tablets White to off-white, capsule shaped tablet with ‘IN 150’ on one side and ‘>’ on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1). A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose is one 150 mg tablet once a month. The tablet should preferably be taken on the same date each month. Ibandronic Acid Tablets should be taken after an overnight fast (at least 6 hours) and 1 hour before the first food or drink (other than water) of the day (see section 4.5) or any other oral medicinal products or supplementation (including calcium). In case a dose is missed, patients should be instructed to take one Ibandronic Acid 150 mg Tablet the morning after the tablet is remembered, unless the time to the next scheduled dose is within 7 days. Patients should then return to taking their dose once a month on their originally scheduled date. If the next scheduled dose is within 7 days, patients should wait until their next dose and then continue taking one tablet once a month as originally scheduled. Patients should not take two tablets within the same week. Patients should receive supplemental calcium and / or vitamin D if dietary intake is inadequate (see section Կարդացեք ամբողջական փաստաթուղթը